与非他汀类药物相比，默克口服PCSK 9恩利肽显示出更好的降低胆固醇的效果

2026-03-31 02:54

New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of low-density lipoprotein cholesterol (LDL-C) compared to oral non-statin medicines.
The CORALreef AddOn study compared enlicitide to ezetimibe, Esperion Therapeutics' (ESPR) Nexletol (bempedoic acid), and a combination of the two drugs.
At eight weeks, enlicitide reduced LDL-C by 64.6% from baseline when added to statin treatment. Other data showed that enlicitide cut LDL-C by 56.7% versus bempedoic acid; 36% versus ezetimibe; and 28.1% versus bempedoic acid with ezetimibe.
Secondary endpoints, such as reductions in apolipoprotein B and non-high-density lipoprotein cholesterol vs. bempedoic acid, ezetimibe, and bempedoic acid/ezetimibe, were also met.
In December, enlicitide was granted an FDA Commissioner National Priority Voucher.
While two PCSK9 inhibitors are already marketed—Amgen's (AMGN) Repatha (evolocumab) and Regeneron Pharmaceuticals' (REGN) Praluent (alirocumab)—they are both given via injection.

More on Merck